These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M. J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387 [Abstract] [Full Text] [Related]
6. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. Feldman SR, Merola JF, Pariser DM, Zhang J, Zhao Y, Mendelsohn AM, Gottlieb AB. J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106 [Abstract] [Full Text] [Related]
7. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Br J Dermatol; 2021 Aug; 185(2):323-334. PubMed ID: 33544883 [Abstract] [Full Text] [Related]
14. Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2. Dykukha I, Schoenenberger A, Kasujee I, Mrowietz U, Vonthein R. Dermatology; 2022 Aug; 238(5):910-918. PubMed ID: 35168231 [Abstract] [Full Text] [Related]
15. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C. J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709 [Abstract] [Full Text] [Related]